Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Invega Hafyera
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Invega Hafyera (paliperidone palmitate 6-month) is an atypical antipsychotic and a long-acting injectable (LAI) prodrug of paliperidone. It is indicated for the treatment of schizophrenia in adults who have been adequately treated with either the 1-month (Invega Sustenna) or 3-month (Invega Trinza) paliperidone palmitate formulations for at least four months. Developed by Janssen, the drug is administered twice yearly via intramuscular injection. Its therapeutic mechanism involves the antagonism of central dopamine D2 and serotonin 5-HT2A receptors, which helps manage the positive and negative symptoms of schizophrenia. The extended-release profile is achieved through the slow dissolution of the palmitate ester at the injection site, followed by hydrolysis into the active moiety, paliperidone.
- Brand names
- Invega Hafyera
- Other names
- paliperidone palmitate 6-monthpaliperidone palmitate 6-monthlypaliperidone palmitate six-month
02
Targets
ADRA1A (α1A)ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR7 (5-hydroxytryptamine receptor 7)
Beyond the preview
Go deeper on Invega Hafyera.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invega Hafyera.